INTRODUCTION
Sleep disorders were frequently reported by opioid-dependent patients during methadone maintenance therapy (MMT) [1] [2] [3] [4] [5] [6] . Patients on MMT demonstrated disrupted sleep including increased stage 2 sleep and decreased REM sleep and stage 1 sleep compared to age, sex, and body mass index (BMI) matched normal subjects [7] . In addition, they reported significantly worse daytime function, were more depressed, and had increased daytime sleepiness when compared to the control subjects [8] . The sleep disturbances among opioid-dependent patients on MMT contributed to premature exit from treatment [9] [10] [11] , increased use of medications (prescribed or ''over the counter'') to help with sleep [1] [2] [3] , and increase in chronic depressive symptoms [8, 12] . The sleep disturbances also impacted on quality of life and could impair engagement with treatment leading to continued drug use [1, 5, 12] .
Previous studies showed that opioids affected sleep by acting on both sleep-and wake-promoting systems at the pontine reticular formation (PRF) and the substantia innominata within the basal forebrain (BF) [13] .
In the PRF, the administration of opioids decreased adenosine levels and this was dependent upon opioid receptor, mu 1 gene (OPRM1) agonism, and subsequently resulted in sleep disturbance-related side effects of opioids [14] .
Opioid drugs, including morphine, fentanyl, and methadone, are agonists of the l-opioid receptor which is encoded by the OPRM1 gene.
It has been suggested that the efficacy and side effects of commonly used opioids are associated with their affinity for l-opioid receptor. Some of the OPRM1 polymorphisms that affect the density and function and consequently the signaling efficacy of l-opioid receptors may contribute to interindividual variations in the response to opioids [15] [16] [17] . 118A[G (dbSNP rs1799971, Asn40Asp) polymorphism is one of the most frequently studied polymorphisms of OPRM1. It is found in exon 1 and may greatly affect the l-opioid receptor N-glycosylation and reduced stability of the receptor in cell cultures [18] . N-Glycosylation plays a part in many cellular processes like receptor folding, sorting, Genotyping Methods for OPRM1 
RESULTS

Characteristics of Study Participants
A total of 165 opioid-dependent patients fulfilled inclusion and exclusion criteria, gave informed consent, and completed the study. [39] . Specifically, 58.8% (N = 97) of patients had PSQI scores greater than 5, indicating they were 'poor sleepers'.
OPRM1 Polymorphisms
The observed allelic frequencies were 40.6% for [19] [20] [21] . The IVS2 ? 691G[C polymorphism is predicted to change the affinity of transcriptional regulatory factors for the intronic DNA sequence and directly alter mRNA levels, and therefore it might change the regulation of OPRM1 gene expression. It was also shown that the DNA intronic sequence can be involved in alternative DNA splicing, resulting in different isoforms of human OPRM1 [20, 22] . On the basis of our results, we suggest that strong linkage disequilibrium (LD) between these polymorphisms and other unstudied polymorphisms [42, 43] formed a series of diplotypes which may affect OPRM1 expression or function (or both) at the site of its action in the brain and resulted in altered binding affinity between endogenous (and/or exogenous) opioid agents and the OPRM1, and hence diplotype differences may contribute to interindividual differences in sleep-disrupting effects of opioids.
Available data indicates that opioids affect sleep by acting on both sleep-and wake-promoting systems at the pontine reticular formation (PRF) and the substantia innominata within the basal forebrain (BF) [13] .
Opioids decreased adenosine levels in the PRF and this is dependent upon OPRM1 agonism, and subsequently resulted in sleep disturbance-related side effects of opioids [14] .
Our results support the hypothesis that patients with AC/AG diplotype had a higher ability to prevent opioid-induced decreases in adenosine and therefore resulted in lower susceptibility to sleep disturbances.
Some limitations to this study need to be highlighted. In our current study, we excluded patients with psychiatric illnesses such as schizophrenia, depression, and anxiety that are commonly associated with sleep disorder; the presence of these illnesses would be expected to increase the severity of sleep problems in our study subjects. Interestingly, although known psychiatric illnesses were one of our exclusion criteria, no participants were excluded because of this criterion. Non-genetic sleep-related factors among patients on MMT were not reported because the focus of the current manuscript was to look into pharmacogenetics factors associated with susceptibility to opioid-induced sleep disturbance among opioid-dependent patients on opioid maintenance therapy.
Patients without the AC/AG diplotype (N = 141, 85.5%) had a mean PSQI score of 5.68 (SD 2.77), slightly above a cutoff score of 5, thus indicating poor overall sleep quality among them [39] . We suggest that sleep disorders should be evaluated and treated among MMT patients, particularly in those without the AC/AG diplotype. Patients with sleep disorders tend to self-medicate to promote sleep or to stay awake during the day [44] . Many of these patients may be at risk of significant drug-drug interactions resulting in ineffective treatment and enhanced side effects of the drugs which could have a profound impact on quality of life, health, and even could impair engagement with treatment leading to continued drug use [1, 5, 12] 
